Cellerys

Über das Unternehmen

Cellerys was founded in 2015 as a spin-out from the University of Zurich, where it conducted a successful phase I clinical trial with the support of Wyss Zurich, a joint accelerator of the University of Zurich and ETH Zurich. The phase I trial showed excellent tolerability and safety and indicated the induction of several tolerance mechanisms.In 2021 Cellerys and Novartis entered a partnership under which Novartis agreed to support the development of RED4MS with a multi-center Phase II clinical trial. The objective of the Phase II trial is to demonstrate proof of concept in this innovative tolerance induction therapy.

So findest du sie

Wagistrasse 21, 8952 Schlieren, SwitzerlandWegbeschreibung →